Použití regorafenibu a SBRT při léčbě plicních metastáz kolorektálního karcinomu

Stáhnout PDF English version

Autoři: Benderli Yasemin Cihan
Působiště autorů: Department of Radiation Oncology, Kayseri Education and Research Hospital, Turkey
Vyšlo v časopise: Klin Onkol 2019; 32(5): 388-389
Kategorie: Short communications
doi: https://doi.org/10.14735/amko2019388

Zdroje

1. Li J, Qin S, Xu R et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16 (6): 619–629. doi: 10.1016/S1470-2045 (15) 70156-7.

2. Qiu H, Katz AW, Chowdhry AK et al. Stereotactic body radiotherapy for lung metastases from colorectal cancer: prognostic factors for disease control and survival. Am J Clin Oncol 2018; 41 (1): 53–58. doi: 10.1097/COC.0000000000000220.

3. Roberto M, Falcone R, Mazzuca F et al. The role of stereotactic body radiation therapy in oligometastatic colorectal cancer: clinical case report of a long-responder patient treated with regorafenib beyond progression. Medicine (Baltimore) 2017; 96 (48): 9023. doi: 10.1097/MD.0000000000009023.

4. Wild AT, Yamada Y. Treatment options in oligometastatic disease: stereotactic body radiation therapy –⁠ focus on colorectal cancer. Visc Med 2017; 33 (1): 54–61. doi: 10.1159/000454685.

5. Gonzalez M, Poncet A, Combescure C et al. Risk factors for survival after lung metastasectomy in colorectal cancer patients: a systematic review and meta-analysis. Ann Surg Oncol 2013; 20 (2): 572–579. doi: 10.1245/s10434-012-2726-3.

6. Gatto L, Nannini M, Saponara M et al. Radiotherapy in the management of gist: state of the art and new potential scenarios. Clin Sarcoma Res 2017; 7 : 1. doi: 10.1186/s13569-016-0065-z.

7. Røed Skårderud M, Polk A, Kjeldgaard Vistisen K et al. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. Cancer Treat Rev 2018; 62 : 61–73. doi: 10.1016/j.ctrv.2017. 10.011.